TSXV:ARCH - Post Discussion
Post by
Riverfolk on Nov 02, 2021 4:24pm
Extremely Undervalued in Comparison to peers
The recent realization by the market has made the Arch chart look incredible, but lets no forget that we are extremely undervalued compared to our peers.
Current Market cap 156 mil US
We are waiting on Phase II Human Clinical Trial Data by a third party for a 20 billion a year unmet market.
BLU is currently 578 mil market cap for Chronic Cough (Phase 2)
VXRT is currently 888 mil market cap US Oral Vaccines
SAVA is 2 billion US market cap for Blood Cancer (Phase 2)
CYDY is 1.1 billion US market cap for Antibodies
TRIL was 2.2 billion buyout (Phase 2)
As we wait on data, there is no reason why we are not at a 600 million market cap of $9.68. We have fully patented new mechanism of action with a drug library. IMHO we will be 10x this current price if data deems it worthy.
Be the first to comment on this post